This study is in progress, not accepting new patients
Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427)
Renal Cell Carcinoma PD1 PD-1 PDL1 PD-L1 Carcinoma Carcinoma, Renal Cell Pembrolizumab
Lead Scientist at UCSF
- Arpita Desai
Dr. Arpita Desai is an oncologist who specializes in the treatment of patients with genitourinary cancers, in particular kidney and prostate cancers. Desai is interested in developing novel imaging and therapeutic strategies in renal cell cancer with the goal of improving outcomes by personalizing therapy.
- in progress, not accepting new patients
- Start Date
- Completion Date
- Merck Sharp & Dohme Corp.
- Phase 2
- Study Type
- Last Updated